# Lyvgen Biopharma

Source: https://onco.cc/companies/lyvgen-biopharma/  
OnCo record `lyvgen-biopharma` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Lyvgen Biopharma is a Shanghai antibody company that builds agonists of immune-activating receptors such as CD137 and CD40; its CD137 antibody LVGN6051 is being tested with PD-1 blockade.

## Summary

Lyvgen Biopharma develops next-generation immuno-oncology antibodies with engineered Fc regions that tune their crosslinking and activity. LVGN6051 is a CD137 (4-1BB) agonist designed to activate T cells within tumours while limiting the liver toxicity seen with earlier agents; it is in phase 1 trials alone and with pembrolizumab or anlotinib. LVGN7409 is a CD40 agonist and LVGN3616 is a PD-1 antibody.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: Lyvgen Biopharma Holdings; 礼进生物
- Tags: drug-maker
- HQ: Shanghai
- Type: biotech
- Website: https://www.lyvgen.com/

## Sources

- Official website: https://www.lyvgen.com/

## Connected records

- drugs: [LVGN6051](https://onco.cc/drugs/lvgn6051/)

---
JSON: https://onco.cc/api/v1/entities/lyvgen-biopharma.json